Undetectable proviral deoxyribonucleic acid in an adolescent perinatally infected with human immunodeficiency virus-1C and on long-term antiretroviral therapy resulted in viral rebound following antiretroviral therapy termination: A case report with implications for clinical care.


Journal

Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R

Informations de publication

Date de publication:
Nov 2019
Historique:
entrez: 26 11 2019
pubmed: 26 11 2019
medline: 4 12 2019
Statut: ppublish

Résumé

Early initiation of antiretroviral therapy (ART) leads to long-term viral suppression, reduces proviral reservoir size, and prolongs time to rebound. Since human immunodeficiency virus (HIV) is a lifelong disease, diagnostic monitoring after confirmed infection is typically not performed; therefore, little is known about the impact of early initiation and long-term ART on the sensitivity of assays that detect HIV antibodies and viral nucleic acid in children and adolescents. Here we report 1 case of diagnosed and confirmed perinatal HIV-1C infection with longstanding viral suppression, who subsequently had a negative HIV-1 deoxyribonucleic acid (DNA) test, undetectable antibodies to HIV-1, and high CD4+ T cell count after 14 years of ART. The patient was diagnosed with HIV in 2002 at 1 and 2 months of age using DNA polymerase chain reaction. At 8 months old, his viral load was 1210 HIV ribonucleic acid (RNA) copies/mL and CD4 T cell count was 3768 cells/mm. At the age of 9 months, highly active antiretroviral therapy comprising of zidovudine, nevirapine, and lamivudine was initiated. The patient remained on this treatment for 14 years 11 months and was virally suppressed. At the age of 14 years 4 months, the participant decided to visit a local voluntary HIV testing center, where a rapid HIV test came out negative and the viral load was undetectable (<400 HIV-1 RNA copies/mL). These results led to termination of ART which led to viral rebound within 9 months. As more people with early HIV infection initiate early ART in the context of "Test and Treat all" recommendations, aspects of this report may become more commonplace, with both clinical and public health implications. If the possibility of functional cure (or false-positive diagnosis) is being considered, decisions to terminate ART should be made cautiously and with expert guidance, and may benefit from highly sensitive quantification of the proviral reservoir.

Identifiants

pubmed: 31764816
doi: 10.1097/MD.0000000000018014
pii: 00005792-201911220-00047
pmc: PMC6882625
doi:

Substances chimiques

DNA, Viral 0

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e18014

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : FIC NIH HHS
ID : D43 TW009610
Pays : United States
Organisme : FIC NIH HHS
ID : D43 TW010543
Pays : United States
Organisme : NIAID NIH HHS
ID : K24 AI131924
Pays : United States

Références

N Engl J Med. 1994 Nov 3;331(18):1173-80
pubmed: 7935654
J AIDS Clin Res. 2013 May 27;Suppl 6:
pubmed: 25328815
N Engl J Med. 2015 Feb 19;372(8):786-8
pubmed: 25693029
Proc Natl Acad Sci U S A. 1997 Nov 25;94(24):13193-7
pubmed: 9371822
Curr Opin HIV AIDS. 2015 Jan;10(1):12-7
pubmed: 25389804
N Engl J Med. 2013 Nov 7;369(19):1828-35
pubmed: 24152233
Retrovirology. 2018 Jan 09;15(1):3
pubmed: 29316955
PLoS Pathog. 2016 Apr 27;12(4):e1005535
pubmed: 27119536
Lancet HIV. 2016 Jan;3(1):e49-54
pubmed: 26762993
Lancet. 2002 Apr 6;359(9313):1178-86
pubmed: 11955535
PLoS Med. 2017 Nov 7;14(11):e1002417
pubmed: 29112956
Lancet. 1999 Mar 6;353(9155):773-80
pubmed: 10459957
AIDS. 1999 May 28;13(8):F59-62
pubmed: 10371167
Lancet. 1999 Mar 6;353(9155):781-5
pubmed: 10459958
N Engl J Med. 2000 Oct 5;343(14):982-91
pubmed: 11018164
Lancet. 1999 Sep 4;354(9181):795-802
pubmed: 10485720
AIDS. 2008 Aug 20;22(13):1583-8
pubmed: 18670217
AIDS. 2006 Jun 12;20(9):1281-8
pubmed: 16816557
J Infect Dis. 2003 Mar 1;187(5):725-35
pubmed: 12599045
J Clin Microbiol. 2016 Apr;54(4):902-11
pubmed: 26763968
Nat Med. 2009 Aug;15(8):893-900
pubmed: 19543283
J Clin Microbiol. 2019 Feb 27;57(3):
pubmed: 30626659
JAMA. 2006 Aug 16;296(7):794-805
pubmed: 16905785
AIDS. 2016 Jan 28;30(3):343-53
pubmed: 26588174
Science. 1997 Nov 14;278(5341):1295-300
pubmed: 9360927
PLoS Pathog. 2013 Mar;9(3):e1003211
pubmed: 23516360
EBioMedicine. 2016 Sep;11:68-72
pubmed: 27460436
Curr Opin HIV AIDS. 2015 Jan;10(1):29-34
pubmed: 25402707
AIDS. 2010 Nov 27;24(18):2803-8
pubmed: 20962613
Nat Med. 2018 Jul;24(7):923-926
pubmed: 29892063
J Virol. 2000 Aug;74(15):6984-91
pubmed: 10888637
J Clin Virol. 2014 Mar;59(3):172-6
pubmed: 24440176
J Pediatr. 2012 Jan;160(1):60-6.e1
pubmed: 21868029

Auteurs

Catherine Kegakilwe Koofhethile (CK)

Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Harvard T.H. Chan School of Public Health, Boston, MA.

Sikhulile Moyo (S)

Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Harvard T.H. Chan School of Public Health, Boston, MA.

Kenanao Peggy Kotokwe (KP)

Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.

Patrick Mokgethi (P)

Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.

Lorato Muchoba (L)

Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.

Selebogo Mokgweetsi (S)

Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.

Tendani Gaolathe (T)

Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.

Joseph Makhema (J)

Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Harvard T.H. Chan School of Public Health, Boston, MA.

Roger Shapiro (R)

Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Harvard T.H. Chan School of Public Health, Boston, MA.

Shahin Lockman (S)

Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Harvard T.H. Chan School of Public Health, Boston, MA.

Phyllis Kanki (P)

Harvard T.H. Chan School of Public Health, Boston, MA.

M Essex (M)

Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Harvard T.H. Chan School of Public Health, Boston, MA.

Simani Gaseitsiwe (S)

Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Harvard T.H. Chan School of Public Health, Boston, MA.

Tulio de Oliveira (T)

College of Health Sciences, Nelson R Mandela School of Medicine, University of KwaZulu-Natal (UKZN).
KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), UKZN, Durban, South Africa.

Vladimir Novitsky (V)

Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Harvard T.H. Chan School of Public Health, Boston, MA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH